Grupo de Investigación en Fisiopatología Cardiovascular
CTS237
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biomedicina de Sevilla (17)
2023
-
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596
2022
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2019
-
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 361-366
2018
-
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort
Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706
2017
-
Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients
HIV Medicine, Vol. 18, Núm. 8, pp. 546-554
-
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study
HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8
2016
-
Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort
PLoS ONE, Vol. 11, Núm. 2
-
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014
BMC Infectious Diseases, Vol. 16, Núm. 1
-
The PNPLA3 genetic variant rs738409 influences the progression to cirrhosis in HIV/ Hepatitis C virus coinfected patients
PLoS ONE, Vol. 11, Núm. 12
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
-
Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C
Journal of Infection, Vol. 71, Núm. 5, pp. 571-577
-
Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals
AIDS, Vol. 29, Núm. 15, pp. 1927-1935
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Risk of liver decompensation among HIV/Hepatitis C virus-coinfected individuals with advanced fibrosis: Implications for the timing of therapy
Clinical Infectious Diseases, Vol. 57, Núm. 10, pp. 1401-1408
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726